Targeting DNA repair to enhance the efficacy of sorafenib in hepatocellular carcinoma

The multityrosine kinase inhibitor sorafenib remains an important systemic treatment option for hepatocellular carcinoma (HCC). Signaling pathways, which are targeted by sorafenib, are involved in checkpoint and DNA repair response, RAD51 being a candidate protein. Here, we aim to evaluate the effec...

Descripción completa

Detalles Bibliográficos
Autores principales: Samadaei, Mahzeiar, Senfter, Daniel, Madlener, Sibylle, Uranowska, Karolina, Hafner, Christine, Trauner, Michael, Rohr‐Udilova, Nataliya, Pinter, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9828257/
https://www.ncbi.nlm.nih.gov/pubmed/36271841
http://dx.doi.org/10.1002/jcb.30340

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9828257/
https://www.ncbi.nlm.nih.gov/pubmed/36271841
http://dx.doi.org/10.1002/jcb.30340

Ejemplares similares